A randomized, open-label phase II study of ZD1839 (Iressa (TM)) versus gemcitabine and carboplatin in chemotherapy-naive patients with advanced (stage IIIB or IV) non-small cell lung cancer and ECOG [Eastern Cooperative Oncology Group] performance status 2

Trial Profile

A randomized, open-label phase II study of ZD1839 (Iressa (TM)) versus gemcitabine and carboplatin in chemotherapy-naive patients with advanced (stage IIIB or IV) non-small cell lung cancer and ECOG [Eastern Cooperative Oncology Group] performance status 2

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2010

At a glance

  • Drugs Carboplatin; Gefitinib; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Nov 2008 Last checked against ClinicalTrials.gov record.
    • 12 Nov 2008 Actual trial completion date identified as June 2008 from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top